327PD - Body mass index and prognosis of women with metastatic breast cancer

Date 01 October 2012
Event ESMO Congress 2012
Session Breast cancer, locally advanced and metastatic
Topics Aetiology, epidemiology, screening and prevention
Breast Cancer
Basic Scientific Principles
Presenter Alessandra Gennari
Authors A. Gennari1, D. Amadori2, O. Nanni2, A. De Censi1, P.F. Conte3, M. Puntoni4, P. Bruzzi5
  • 1Medical Oncology, SC Oncologia, 16128 - Genoa/IT
  • 2Medical Oncology, IRST - Meldola, 47014 - Meldola/IT
  • 3Dept. Of Hematology/oncology, Ospedale Policlinico-Modena, IT-41100 - Modena/IT
  • 4Eo Galliera, SC Oncologia, 16128 - Genoa/IT
  • 5Clinical Epidemiology, IST-San Martino, 16125 - Genoa/IT



Obesity is a well known risk factor for the development of breast cancer and an adverse prognostic factor in those women who have already been diagnosed with breast cancer. However, the effect of obesity on the prognosis of MBC women has not been explored so far. The aim of this study was to evaluate the influence of Body Mass Index (BMI) on the prognosis of MBC patients receiving first line chemotherapy.


The relationship between BMI (kg/m2), and progression free (PFS) or overall survival (OS) was assessed in 698 MBC patients enrolled in 3 clinical trials of first line chemotherapy, conducted by the same collaborative group. Conventional WHO BMI definitions were applied: normal 18.5-24.9 kg/m2, overweight 25-30 kg/m2, obese >30 kg/m2. PFS and OS were calculated by Kaplan-Meier estimation; multivariate Cox analysis was performed adjusting for age, menopausal status, PS and study.


Information on BMI at the time of study entry, was available on 489 women. All patients received first line chemotherapy regimens including anthracyclines and taxanes, either in sequence or combination. Median follow up was 18 months (range 0.4 to 88.3). Overall, 40.3% of the patients were normal, 38.2% were overweight and 21.5% were obese. Median age was 57 years (range 25 to 73); PS was 0 in 93% of the patients. A non significant trend toward improved PFS was found in overweight women: median PFS was 13.1 months (95% CI 11.0-15.2) in BMI 25-30 versus 10.8 months (8.9-12.6) in BMI < 25 and 12.2 (95% CI 10.4-14.0) in BMI >30, p = 0.2. Median OS was 32.0 months (95% CI 24.9-39.1) in BMI < 25 versus 32.9 (95% CI 27.7-38.1) in BMI 25-30 and 30.7 (95% CI 24.3-37.0) in BMI >30, p = 0.8. By multivariate analysis, none of the considered variables was significantly associated with differences in PFS and/or OS.


In this study BMI at baseline was not significantly associated with the outcome of MBC patients treated with first line chemotherapy; however, a non significant trend for an improved PFS was observed in overweight women as compared to normal weight and obese patients. These data suggest that overweight should not be regarded as an adverse prognostic factor patients with MBC.


All authors have declared no conflicts of interest.